MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) (MDMA-CBT4OCD)
This PhaseII interventional trial (n=40), titled “MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II Study,” aims to assess the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).
Details
Randomised, parallel-group Phase II trial comparing MDMA-assisted CBT (80 mg with optional 40 mg supplemental dose 1.5–2 h later) versus methamphetamine-assisted CBT (10 mg with optional 5 mg supplemental) in adults with moderate–severe OCD (Y-BOCS ≥16).
Primary purpose is treatment; outcomes include safety, tolerability, and preliminary effectiveness on OCD symptoms alongside therapist-delivered CBT with exposure and response prevention.